Skip to content
Disclosery

JOHNSON & JOHNSON

Follow

13F filer, CIK 200406, NEW BRUNSWICK, NJ

JOHNSON & JOHNSON reported $334,096,397 across 20 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-07-22. Its ten largest share positions make up 97.27% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000904454-25-000367

Period
2025-06-30
Reported value
$334M
Holdings
20
Top 10 weight
97.27%
New
0
Sold out
0

Part of the filer group JOHNSON & JOHNSON

How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELL IMMUNOPHARMA INCreduced-782,152-$6.99M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000904454-25-000367, largest first. % of portfolio is the value over $334,096,397, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,449,183 shares; 2024Q4: 2,449,183 shares; 2025Q1: 2,449,183 shares; 2025Q2: 2,449,183 shares 2,449,183$136M40.83%0Timeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,641,064 shares; 2024Q4: 6,641,064 shares; 2025Q1: 6,641,064 shares; 2025Q2: 6,641,064 shares 6,641,064$43.9M13.14%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,498,051 shares; 2024Q4: 2,498,051 shares; 2025Q1: 2,498,051 shares; 2025Q2: 2,498,051 shares 2,498,051$28.6M8.55%0Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 814,586 shares; 2024Q4: 814,586 shares; 2025Q1: 814,586 shares; 2025Q2: 814,586 shares 814,586$28.2M8.44%0Timeline
NBTXNANOBIOTIXQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,623,816 shares; 2024Q4: 5,623,816 shares; 2025Q1: 5,623,816 shares; 2025Q2: 5,623,816 shares 5,623,816$25.5M7.62%0Timeline
CVRXCVRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,103,430 shares; 2024Q4: 4,103,430 shares; 2025Q1: 4,103,430 shares; 2025Q2: 4,103,430 shares 4,103,430$23.9M7.15%0Timeline
PRCTPROCEPT BIOROBOTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 357,939 shares; 2024Q4: 357,939 shares; 2025Q1: 357,939 shares; 2025Q2: 357,939 shares 357,939$20.4M6.1%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,979,173 shares; 2024Q4: 1,979,173 shares; 2025Q1: 1,979,173 shares; 2025Q2: 1,979,173 shares 1,979,173$8.13M2.43%0Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 748,062 shares; 2024Q4: 748,062 shares; 2025Q1: 748,062 shares; 2025Q2: 748,062 shares 748,062$6.09M1.82%0Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 247,598 shares; 2024Q4: 247,598 shares; 2025Q1: 247,598 shares; 2025Q2: 247,598 shares 247,598$3.98M1.19%0Timeline
FATEFATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,379,064 shares; 2024Q4: 3,379,064 shares; 2025Q1: 3,379,064 shares; 2025Q2: 3,379,064 shares 3,379,064$3.51M1.05%0Timeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,849,445 shares; 2024Q4: 1,849,445 shares; 2025Q1: 1,849,445 shares; 2025Q2: 1,849,445 shares 1,849,445$1.4M0.42%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,636,363 shares; 2024Q4: 3,636,363 shares; 2025Q1: 3,636,363 shares; 2025Q2: 3,636,363 shares 3,636,363$1.21M0.36%0
VOR BIOPHARMA INCVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,074,658 shares; 2024Q4: 1,074,658 shares; 2025Q1: 1,074,658 shares; 2025Q2: 1,074,658 shares 1,074,658$1.14M0.34%0
NNOXNANO X IMAGING LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 158,852 shares; 2024Q4: 158,852 shares; 2025Q1: 158,852 shares; 2025Q2: 158,852 shares 158,852$831K0.25%0Timeline
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 311,967 shares; 2024Q4: 311,967 shares; 2025Q1: 311,967 shares; 2025Q2: 311,967 shares 311,967$371K0.11%0Timeline
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 823,317 shares; 2025Q1: 823,317 shares; 2025Q2: 41,165 shares 41,165$368K0.11%-782,152
ADICET BIO INCADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 364,472 shares; 2024Q4: 364,472 shares; 2025Q1: 364,472 shares; 2025Q2: 364,472 shares 364,472$228K0.07%0
BIOMX INCBIOMX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 192,321 shares; 2024Q4: 96,866 shares; 2025Q1: 96,866 shares; 2025Q2: 96,866 shares 96,866$42.6K0.01%0
SENSEONICS HLDGS INCSENSEONICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 54,621 shares; 2024Q4: 54,621 shares; 2025Q1: 54,621 shares; 2025Q2: 54,621 shares 54,621$27K0.01%0

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000904454-25-000367 base2025-07-22acceptance time not in the bulk data set